These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 30804405)

  • 21. Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring
    Cheruiyot A; Li S; Nonavinkere Srivatsan S; Ahmed T; Chen Y; Lemacon DS; Li Y; Yang Z; Wadugu BA; Warner WA; Pruett-Miller SM; Obeng EA; Link DC; He D; Xiao F; Wang X; Bailis JM; Walter MJ; You Z
    Cancer Res; 2021 Sep; 81(17):4499-4513. PubMed ID: 34215620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.
    Rombaut D; Lefèvre C; Rached T; Bondu S; Letessier A; Mangione RM; Farhat B; Lesieur-Pasquier A; Castillo-Guzman D; Boussaid I; Friedrich C; Tourville A; De Carvalho M; Levavasseur F; Leduc M; Le Gall M; Battault S; Temple M; Houy A; Bouscary D; Willems L; Park S; Raynaud S; Cluzeau T; Clappier E; Fenaux P; Adès L; Margueron R; Wassef M; Alsafadi S; Chapuis N; Kosmider O; Solary E; Constantinou A; Stern MH; Droin N; Palancade B; Miotto B; Chédin F; Fontenay M
    Nat Commun; 2024 Apr; 15(1):3016. PubMed ID: 38589367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. m
    Cieśla M; Ngoc PCT; Muthukumar S; Todisco G; Madej M; Fritz H; Dimitriou M; Incarnato D; Hellström-Lindberg E; Bellodi C
    Mol Cell; 2023 Apr; 83(7):1165-1179.e11. PubMed ID: 36944332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
    Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
    Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
    [No Abstract]   [Full Text] [Related]  

  • 26. Splicing factor mutant myelodysplastic syndromes: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.
    Kataoka N; Matsumoto E; Masaki S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
    Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
    Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic
    Foy A; McMullin MF
    J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
    Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
    Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
    Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
    Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A variant erythroferrone disrupts iron homeostasis in
    Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
    Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
    Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
    Visconte V; Rogers HJ; Singh J; Barnard J; Bupathi M; Traina F; McMahon J; Makishima H; Szpurka H; Jankowska A; Jerez A; Sekeres MA; Saunthararajah Y; Advani AS; Copelan E; Koseki H; Isono K; Padgett RA; Osman S; Koide K; O'Keefe C; Maciejewski JP; Tiu RV
    Blood; 2012 Oct; 120(16):3173-86. PubMed ID: 22826563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.
    Pollyea DA; Kim HM; Stevens BM; Lee FF; Harris C; Hedin BR; Knapp JR; O'Connor BP; Jordan CT; Pietras EM; Tan AC; Alper S
    J Leukoc Biol; 2021 Jul; 110(1):197-205. PubMed ID: 33155727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
    Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
    Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations.
    Flach J; Jann JC; Knaflic A; Riabov V; Streuer A; Altrock E; Xu Q; Schmitt N; Obländer J; Nowak V; Danner J; Mehralivand A; Hofmann F; Palme I; Jawhar A; Wuchter P; Metzgeroth G; Nolte F; Hofmann WK; Nowak D
    Haematologica; 2021 Nov; 106(11):2906-2917. PubMed ID: 33054116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
    Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths.
    Cortés-López M; Chamely P; Hawkins AG; Stanley RF; Swett AD; Ganesan S; Mouhieddine TH; Dai X; Kluegel L; Chen C; Batta K; Furer N; Vedula RS; Beaulaurier J; Drong AW; Hickey S; Dusaj N; Mullokandov G; Stasiw AM; Su J; Chaligné R; Juul S; Harrington E; Knowles DA; Potenski CJ; Wiseman DH; Tanay A; Shlush L; Lindsley RC; Ghobrial IM; Taylor J; Abdel-Wahab O; Gaiti F; Landau DA
    Cell Stem Cell; 2023 Sep; 30(9):1262-1281.e8. PubMed ID: 37582363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.